Brokers Issue Forecasts for MRVI Q3 Earnings

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) – Investment analysts at KeyCorp issued their Q3 2027 earnings estimates for shares of Maravai LifeSciences in a research note issued to investors on Wednesday, November 11th. KeyCorp analyst P. Knight anticipates that the company will post earnings per share of ($0.05) for the quarter. KeyCorp currently has an “Overweight” rating and a $11.00 price target on the stock. The consensus estimate for Maravai LifeSciences’ current full-year earnings is ($0.16) per share.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. The company had revenue of $45.85 million during the quarter, compared to analysts’ expectations of $43.56 million. Maravai LifeSciences had a negative net margin of 30.83% and a negative return on equity of 12.44%.

MRVI has been the subject of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Wednesday, August 26th. Wells Fargo & Company boosted their price objective on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a report on Friday, August 7th. TD Cowen assumed coverage on Maravai LifeSciences in a research report on Monday, October 5th. They issued a “buy” rating and a $9.00 target price on the stock. UBS Group upped their target price on Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a research report on Wednesday, September 9th. Finally, Wall Street Zen upgraded Maravai LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Maravai LifeSciences has a consensus rating of “Moderate Buy” and a consensus price target of $8.10.

View Our Latest Report on MRVI

Maravai LifeSciences Trading Down 1.9%

Shares of Maravai LifeSciences stock opened at $7.40 on Monday. The company has a current ratio of 4.66, a quick ratio of 2.98 and a debt-to-equity ratio of 0.51. Maravai LifeSciences has a 12-month low of $2.80 and a 12-month high of $9.42. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -17.21 and a beta of 0.61. The firm’s 50 day simple moving average is $7.40 and its two-hundred day simple moving average is $5.44.

Institutional Investors Weigh In On Maravai LifeSciences

Large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its holdings in Maravai LifeSciences by 24.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 2,043,668 shares of the company’s stock worth $15,654,000 after buying an additional 402,371 shares during the period. Entropy Technologies LP purchased a new position in Maravai LifeSciences during the 3rd quarter worth approximately $155,000. Marshall Wace LLP lifted its stake in Maravai LifeSciences by 38.2% during the 3rd quarter. Marshall Wace LLP now owns 2,034,070 shares of the company’s stock valued at $15,581,000 after acquiring an additional 562,593 shares during the period. Caxton Associates LLP lifted its stake in Maravai LifeSciences by 71.8% during the 3rd quarter. Caxton Associates LLP now owns 193,290 shares of the company’s stock valued at $1,481,000 after acquiring an additional 80,811 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Maravai LifeSciences during the 3rd quarter valued at approximately $5,259,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

(Get Free Report)

Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.

Recommended Stories

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.